Press Release

HIROTSU BIO SCIENCE INC. Takaaki Hirotsu, our CEO joined ‘UBS Disruptive Technology CEO Summit 2023’


HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)) has joined “UBS Disruptive Technology CEO Summit” in Hong Kong on October 12, 2023.

UBS Disruptive Technology CEO Summit 2023

‘UBS Disruptive Technology CEO Summit’ is an international summit organized by UBS Bank that brings together innovative technology companies and technologists from around the world. The 9th edition will explore the apex of transformative technological innovation. This year, we acknowledge the pivotal role of innovation in navigating a rapidly evolving landscape, fully embracing the essence of our theme – “Innovative Minds, Transformative Times.”

Our CEO, Takaaki Hirotsu, was invited as a speaker at the summit and gave a lecture on the theme of “A Future of Early-Stage Cancer Detection”. After the lecture, many entrepreneurs and investors from various countries expressed their admiration and expectations for our R&D technology and its usefulness as a primary screening test. We will continue to strive to create a world where cancer can be detected at an early stage using our unique technology.

■ About HIROTSU Bio Science
We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put to practical use thanks to our researchers’ abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these socials issued with our groundbreaking “bio-diagnoses” technology that utilized that power of nematodes. These nematodes have an excellent sense of smell and are no match to artificial devices.
Furthermore, in June of 2023, we as HIROTSU signed a memorandum of understanding with the Global Health Equity Fund, an impact fund established in partnership with the WHO Foundation, and also the venture capital firm ‘Our Crowd’ who strives to support the creation of impact to solve global health problem, regarding the overseas expansion of N-NOSE to countries with inadequate healthcare systems. For the healthy future of many people, we are striving for research, development, and practical application to make bio-diagnosis more accessible and progressive.

Company Name:
 HIROTSU Bio Science Inc.
 New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo
Name of Representative:
 Takaaki Hirotsu, CEO
Date of Establishment:
 August 2016
Main Service:
 Research, development, and marketing of cancer screenings using nematode and nematode olfactory sensors
Corporate website:

■ About “N-NOSE”
A primary cancer screening test that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode C. elegans, which has an excellent sense of smell. By just submitting urine, it is a simple, inexpensive, highly accurate, and comprehensive systemic cancer test. The test has been proven to detect 15 types of cancer: oral cavitypharynx cancer, esophagus cancer, lung cancer, breast cancer, stomach cancer, liver cancer, pancreas cancer, gall bladder cancer, bile duct cancer, colon cancer, kidney cancer, bladder cancer, ovary cancer, uterus cancer, prostate cancer, etc. Since its launch in January 2020, a total of over 400,000 people have been tested. The number of corporate customers has exceeded 1,700 (as of July 2023). From 2023, we will also launch “N-NOSE plus Pancreas” as a next-generation “cancer type specific test” of N-NOSE, and “N-NOSE Dog” and “N-NOSE Cat” as cancer risk tests for pets.

Official service website :

Download details / PRESS RELEASE(PDF)